F-star Entered into a Collaboration and Licence Agreement with Takeda to Discover and Develop Multi-Specific Antibodies
- F-star will receive up front & research funding, ~$1B upon achievement of milestones across multiple programs along with royalties on annual net sales of any commercial product that resulted from an agreement. Both companies will jointly research & develop novel Fcab domains against immuno-oncology targets
- Takeda will receive an exclusive royalty-bearing license globally to research, develop, and commercialize Abs incorporating Fcab domains while F-star will hold the right to research, develop, and commercialize Abs incorporating certain other Fcab domains
- The collaboration focuses on research and developing multi-specific immunotherapies for cancer using F-star’s fully-human Fcab & tetravalent mAb² platforms
Ref: GlobalNewswire | Image: F-star
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.